|
New Clinical Perspectives in the Management of Myelofibrosis
STATEMENT OF NEED
Myelofibrosis is a rare type of myeloproliferative neoplasm—a heterogenous group of hematopoietic disorders—that affects approximately 13,000 individuals in the United States. As symptoms do not typically manifest in early stages, patients with myelofibrosis often present with advanced disease. The presence of comorbidities precludes most from allogeneic stem cell transplant, the only potentially curative treatment option available. Due to the dearth of effective treat... |
|
|
Nursing Management of Myelofibrosis: Controlling Symptoms and Optimizing Patient Quality of Life
STATEMENT OF NEED
Myeloproliferative neoplasms are a heterogeneous group of hematopoietic disorders that includes myelofibrosis, polycythemia vera (PV), and essential thrombocythemia (ET). These malignancies affect approximately 13,000, 134,000, and 148,000 individuals in the United States, respectively. As symptoms do not typically manifest in early stages, patients with MPNs often present with advanced disease. The presence of comorbidities precludes most from potentially curative allogen... |
|
|
Virtual Tumor Board: Diagnosis and Management of Myelodysplastic Syndromes
STATEMENT OF NEED
Myelodysplastic syndromes (MDS) are a group of heterogeneous hematopoietic disorders derived from an abnormal multipotent progenitor cell, characterized by ineffective hematopoiesis, bone marrow failure, and peripheral blood cytopenias. Survival in MDS ranges from a median of 5.3 years in lower-risk patients to as little as 0.8 years in higher-risk patients. Mortality is usually a result of infection, hemorrhage, and/or iron overload secondary to red blood cell transfusion... |
|
|
Acute Myeloid Leukemia: What’s New on the Horizon
Rapid progress in the treatment of Acute Myeloid Leukemia (AML) has resulted in a substantial volume of new clinical literature and updated guidelines. 8 new therapies have been approved since 2017 alone. Clinicians must remain well-versed with novel treatment options for newly diagnosed patients and those with relapsed/refractory AML and need education on advances in targeted therapies for AML.
This expert live recording from a series of national visiting lecture series updates clinicians ... |
|